NCT06208150 · Interventional trial
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Overall registry status Active not recruiting
Phase 3
Conditions Multiple Myeloma
Delaware Valley sites
- Thomas Jefferson University · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory